18 F]FPEB is a promising PET radioligand for the metabotropic glutamate receptor 5 (mGluR5), a potential target for the treatment of neuropsychiatric diseases. The purpose of this study was to evaluate the test-retest reproducibility of [ 18 F]FPEB in the human brain. Methods Seven healthy male subjects were scanned twice, 3 -11 weeks apart. Dynamic data were acquired using bolus plus infusion of 162±32 MBq [ 18 F]FPEB. Four methods were used to estimate volume of distribution (V T ): equilibrium analysis (EQ) using arterial (EQ A ) or venous input data (EQ V ), MA1, and a two-tissue compartment model (2 T). Binding potential (BP ND ) was also estimated using cerebellar white matter (CWM) or gray matter (CGM) as the reference region using EQ, 2 T and MA1. Absolute test-retest variability (aTRV) of V T and BP ND were calculated for each method.
Introduction
Glutamate is the most abundant excitatory neurotransmitter in the human brain, mediating 70 -90 % of synaptic transmissions [1] . Physiological functions regulated by glutamate include brain development, learning and memory, and longterm potentiation [1] [2] [3] . Not surprisingly, dysfunction in the glutamate system is associated with a variety of pathological conditions such as drug addiction, schizophrenia, anxiety, mood disorders, pain, epilepsy, stroke, Alzheimer's disease, Electronic supplementary material The online version of this article (doi:10.1007/s00259-015-3094-6) contains supplementary material, which is available to authorized users.
Parkinson's disease, Huntington's disease, and fragile X syndrome [4, 5] .
Glutamate receptors are classified into ionotropic receptors (iGluRs) and metabotropic receptors (mGluRs). iGluRs mediate fast excitatory neurotransmission and NMDA, AMPA, and kainate receptors fall into this category; while the mGluRs mediate slower, modulatory neurotransmission and are comprised of eight subtypes (mGluR1-8) organized into three groups (I, II, and III) based on their pharmacological and signal transduction properties. mGluRs are coupled to their associated iGluRs by a second messenger cascade and modulate the function of iGluRs [6, 7] . iGluRs have received great attention as therapeutic targets for drug addiction and various forms of relapse-like behavior based on evidence from animal studies. However, iGluR antagonists have shown serious side effects in humans and interest has shifted to modulating glutamate transmission via mGluRs [5] .
Group I mGluRs (mGluR1 and 5) are mainly located postsynaptically at the periphery of postsynaptic densities, while group II and III mGluRs are present primarily in the presynaptic terminals [1, 8] . mGluR5 is structurally linked to the NMDA receptor; it produces positive modulation of NMDA receptor function, and activation of NMDA receptors enhances mGluR5 responses [5, 6, 9] . This synergistic action activates a number of Ca 2+ -regulated proteins and leads to an increase in AMPA receptor activity [6, 9] . Selective mGluR5 ligands have been shown or are believed to have therapeutic potential for neuropsychiatric diseases through this receptor crosstalk. For example, mGluR5 agonists and positive allosteric modulators are believed to improve memory function in Alzheimer's disease by increasing neuronal excitability and synaptic plasticity, while mGluR5 antagonists and negative allosteric modulators could be potential treatments for epilepsy and multiple sclerosis by way of their neuroprotective effects against glutamate excitotoxicity [4] .
The ability to detect changes in mGluR5 availability in vivo could be valuable for elucidating functional and dysfunctional glutamate transmission in the brain and facilitating therapeutic drug development targeting mGluR5. [ 18 F]FPEB is a promising PET radioligand that binds to mGluR5 with high specificity and selectivity [10, 11] . The purpose of this study was to evaluate test-retest reproducibility of [ 18 F]FPEB binding using high-resolution PET imaging in healthy humans. Kinetic modeling and equilibrium analysis methods to quantify [ 18 F]FPEB binding were evaluated. Specifically, we tested if a shorter equilibrium measurement, instead of a 2-h dynamic PET scan, was sufficient to derive reliable binding parameters. Venous input functions were also compared with arterial data for equilibrium analysis to examine their usability in estimating [ 18 F]FPEB volume of distribution (V T ).
Materials and methods

Subjects
Seven healthy male subjects (mean age 27±7 years, range 19 -38 years, body weight 83±17 kg, body mass index 26 ±4 kg/m 2 ) were studied under a protocol approved by the Yale Human Investigation Committee, the Yale-New Haven Hospital Radiation Safety Committee, and the Yale University Radiation Safety Committee. Subjects were examined by a physician to exclude major medical conditions or neurological disorders. Electrocardiography, complete blood counts, serum chemistries, thyroid function test, liver function test, urinalysis and urine toxicology screening were performed during screening. The Structured Clinical Interview for DSM-IV axis I Disorders (SCID-CV) [12] was administered to rule out axis I psychiatric disorders. Written informed consent was obtained from all subjects before the study after complete explanation of the study procedures.
Brain magnetic resonance imaging
Brain magnetic resonance (MR) scans were acquired using a 3-T scanner (Trio; Siemens Medical Systems, Erlangen, Germany) for registration with PET and region-of-interest (ROI) definition. MR scans were performed within 2 -3 weeks of the first PET scan, except in one subject whose MR scan was performed 3 months before the first PET scan. A 3D T1-weighted gradient-echo (MPRAGE) sequence with 1 mm 3 isometric resolution (FA 7°, TE 3.34 ms, TI 1,100 ms, and TR 2,500 ms) was used.
Brain [
18 F]FPEB PET scanning [ 18 F]FPEB was synthesized using a previously published method [13] . Average specific activity was 195±47 MBq/ nmol (n=14) at the end of synthesis. To evaluate test-retest variability (TRV), two scans were performed on separate days, 3 to 11 weeks apart. The mean time-of-day difference in injection times between test and retest days was 142±91 min. All procedures for the test and retest scans were identical. PET scans were acquired on a high-resolution research tomograph (HRRT) scanner (Siemens/CTI, Knoxville, TN), with a spatial resolution (full-width at half-maximum) of 2 -3 mm. A radial artery catheter was inserted at the wrist area to measure the metabolite-corrected input function. A venous catheter was inserted at the antecubital area on the same side as the arterial catheter for intravenous administration of [ 18 F]FPEB. Another venous catheter was placed on the contralateral side for venous sampling to compare the venous blood-derived input function with the arterial blood-derived input function.
Before the scan, an optical motion-tracking tool was fastened to the subject's head via a Lycra swim cap. A 6-min transmission scan using an orbiting 137 Cs point-source was obtained for attenuation correction. Emission data were acquired in list mode for 120 min along with bolus plus infusion administration of [ 18 F]FPEB. The injected dose was 162± 32 MBq with specific activity of 145±50 MBq/nmol at the time of injection (n = 14). The injected mass was 0.32 ± 0.14 μg. For the bolus plus infusion paradigm, a K bol value of 190 min was used based on our previous study [14] Dynamic scan data were reconstructed with corrections for attenuation, normalization, randoms, scatter, dead time, and motion (Vicra; NDI Systems, Waterloo, Ontario, Canada), using the ordered-subsets expectation maximization-based MOLAR algorithm [15] .
Input function measurement
The arterial input function was obtained from the time-activity curve (TAC) of the metabolite-corrected arterial concentration of [ To measure f p , triplicate 300-μL aliquots of plasma separated from blood collected prior to tracer injection and mixed with the radiotracer were pipetted into ultrafiltration units and centrifuged at room temperature (20 min at 1,228 g). Plasma and ultrafiltrate activities were counted, and f p was calculated as the ratio of ultrafiltrate activity to total plasma activity. The same procedure was applied to arterial and venous blood.
For the first 7 min after injection (p.i.), continuous arterial blood activity measurements were made with an automated blood counting system drawing blood at 4 mL/min (PBS-101; Veenstra Instruments, Joure, The Netherlands). Thirteen individual blood samples were drawn at 3, 8, 12, 15, 20, 25, 30, 45, 60, 75, 90, 105 , and 120 min after administration of [ 18 F]FPEB, and whole blood and plasma were counted. HPLC was performed at selected time-points and the parent fraction was determined by the ratio of counts in the parent peak to the total counts collected. The parent fractions were fitted to a three-parameter function (one exponential plus a constant) bounded to be ≤1. The final metabolite-corrected arterial concentration of [ 18 F]FPEB was calculated from the product of plasma radioactivity and the parent fractions.
Full arterial input functions were not available for retest scans in three subjects: two subjects were unable to tolerate the arterial line and the automated blood counting system failed in the other subject (arterial samples during the equilibrium period were available in this subject). In these three subjects, the input functions used for equilibrium analysis using arterial data (EQ A ), two-tissue compartment model (2 T), and multilinear analysis 1 (MA1) were calculated from each subject's test data, scaled by the ratio of injected doses in the test and retest scans.
Venous input functions were obtained and compared with arterial input function, in order to determine if less invasive venous blood samples could be used instead of arterial ones when estimating V T using equilibrium analysis (EQ). The parent fractions were averaged from 90 to 120 min. The venous input function was obtained from the TAC of the metabolitecorrected venous concentration of [ 18 F]FPEB (C V ). This curve was only obtained for the latter portion of the curve, specifically from five individual blood samples manually drawn at 60, 75, 90, 105, and 120 min.
The relative difference in f p between arterial and venous blood was calculated as [(arterial f p − venous f p )/arterial f p ]· 100 (%). The relative difference between C A and C V was calculated as [(C A − C V )/C A ]·100 (%).
ROI delineation
ROIs from the AAL (Anatomical Automatic Labeling for SPM2) template were used. In order to apply these template ROIs to the native PET images to compute regional TACs for these ROIs, summed PET images from 0 to 10 min p.i. were coregistered to each subject's T1-weighted MR images using a six-parameter mutual information algorithm (FLIRT, FSL 3.2; Analysis Group, FMRIB, Oxford, UK), which was then coregistered to the MR template by nonlinear transformation using the BioImage Suite software (version 2.5; http://www. bioimagesuite.com). Finally, the ROI voxel coordinates in native PET space were computed using these two transforms in order to generate the TACs. The ROIs were: caudate (16 cm 
Kinetic analysis
The distribution volume (V T ) of [ 18 F]FPEB was estimated by four different analysis methods: two equilibrium analysis [16, 17] methods using arterial and venous blood data (EQ A and EQ V , respectively), 2 T, and MA1 (t*=30 min) [18] . With EQ, once equilibrium is achieved in the tissue and the blood, V T can be measured directly from the concentration ratio of a tracer in the tissue (C T ) to that in plasma. V T was measured as the ratio of the average C T and C A values from 90 to 120 min p.i. (EQ A,90-120 ). Different time windows were also evaluated in order to test if earlier and/or shorter scans were feasible. Specifically, 30-min time windows were tested by shifting the starting time by 10 min down to 60 min (80 -110 min, 70 -100 min, and 60 -90 min). Fifteen-minute time windows of 105 -120 min, 90 -105 min, 75 -90 min, and 60 -75 min were also tested. V T was also measured using venous data (EQ V,90-120 ). The quality of equilibrium was assessed by calculating the rate of change (%/h) for C T , C A , and C V . In addition, V T corrected for f P (V T /f P ) was calculated from the four analysis methods in order to test if f P correction affected test-retest reliability.
Even though a validated reference region is not available for [
18 F]FPEB [19, 20] , it is sometimes the case that calculation of an apparent binding potential (BP ND ) using a region with a small quantity of specific binding can be useful. Therefore, apparent BP ND was calculated as V T V T; CWM −1 using CWM as the reference region. This region showed the lowest uptake of [ 18 F]FPEB in our previous study [14] . BP ND was also calculated using CGM as the reference region for comparison.
Test-retest reliability
To evaluate the test-retest reliability of [ if binding values across the ROIs tend to be higher in the test scan than the retest, mean TRV will be positive, and if there is no such trend, it will be zero. SD of TRV estimates uncertainty in the percent change between the two scans. Mean of aTRV combines both trend and variability of change in [ 18 F]FPEB binding, and thus can be complex if there is a systematic trend. In the absence of such a trend, the mean of aTRV is approximately equal to the percent uncertainty in one single scan value, and is thus smaller than the SD of TRV, which is the percent uncertainty in the difference between the two scans. The intersubject variability was measured using the coefficient of variation (CoV) for all ROIs.
To evaluate within-subject variability relative to between-subject variability, intraclass correlation coefficient (ICC) values were computed for each region as
Þ , where BSMSS indicates the between-subject mean sum of squares and WSMSS indicates the within-subject mean sum of squares. ICC varies from −1 (no reliability) to +1 (perfect reliability, i.e., identical measurements between test and retest studies). 
Statistical analysis
Results
Injection parameters were similar between the test and retest scans ( Table 1) . Mean tissue TACs of all ROIs from the 14 test and retest scans are shown in Fig. 1 . High uptake areas were the anterior cingulate, frontal, temporal, parietal, and occipital cortices, hippocampus, caudate nucleus, and putamen. Medium uptake was observed in the posterior cingulate cortex, pallidum, and thalamus. Uptake was low in the CGM and the lowest in the CWM.
For most regions, equilibrium was reached by 90 min. In all regions except the CWM, the rate of change of C T between 90 and 120 min was −5±9 %/h (mean±SD), and was smaller in high-uptake regions (mean −3 %/h) than medium-uptake regions (mean −8 %/h). For the CWM, the rate of change of C T was −15 ±26 %/h. The hippocampus (5±5 %/h) and the thalamus (−9± 10 %/h) did not show significantly different stability of uptake from that found in our previous study with five subjects [14] .
Comparison of 2 T, MA1, and EQ methods for V T calculation
Regional V T estimates derived from four different analysis methods are shown in Table 2 . By any method, the anterior cingulate cortex had the highest V T and the CWM had the lowest among the ROIs examined. Values of V T estimated with the different methods agreed well with each other (Fig. 2) . For example, V T values estimated from MA1 had excellent correlation with those estimated from 2 T (V T(MA1) =0.99 ⋅ V T(2T) , r 2 =0.99). Values of V T estimated from EQ A,90-120 also had good correlation with those from 2 T (V T(EQA,90-120) =1.09 ⋅ V T(2T) , r 2 =0.93), although EQ A,90-120 overestimated V T in all ROIs by a mean of 9 %. The 9 % mean difference was common to all regions (Fig. 2) , i.e., all regions showed similar behavior. Values of V T estimated from EQ V,90-120 had somewhat worse correlation with those from 2 T (V T(EQV,90-120) =1.07 ⋅ V T(2T) , r 2 =0.83), and overestimated V T in all ROIs by a mean of 7 %. The intersubject variability measured in terms of mean CoV across the ROIs was smallest for 2 T (13.7 %) and MA1 (13.5 %), and largest for EQ V,90-120 (22.2 %). Mean CoV for EQ A,90-120 was 18.2 %. Regional BP ND values derived from the three methods using the CWM as the reference region are shown in Table S1 and Fig. S1 of the Online Resource.
Test-retest variability of V T Mean TRVof V T ranged from −13 to −9 % for 2 T, from −12 to −9 % for MA1, from −6 to −2 % for EQ A,90-120, and from 0 to 4 % for EQ V,90-120 across the ROIs (Table 3) . EQ A,90-120 and EQ V,90-120 had the smallest mean TRV. Test V T values were lower than retest values in most ROIs in six of seven subjects analyzed with 2 T and MA1, but this difference was not significant. The SD of TRV ranged from 13 % to 18 % for 2 T, 11 % to 16 % for MA1, 11 % to 18 % for EQ A,90-120 , and 13 % to 22 % for EQ V,90-120 (Table 4 ). Among the methods there was little overall difference in SD of TRV. Mean aTRV ranged from 12 % to 16 % for 2 T and MA1, and 9 % to 12 % for EQ A,90-120 , and 10 % to 16 % for EQ V,90-120 (Table 5 ). The EQ methods thus provided slightly better results than the kinetic methods. This was also true when evaluated in terms of ICC. ICC ranged from 0.71 to 0.92 for 2 T, 0.72 to 0.93 for MA1, 0.82 to 0.97 for EQ A,90-120 , and 0.87 to 0.98 for EQ V,90-120 (Table 6 ). TRV and ICC of BP ND are shown in Table S2 of the Online Resource.
Plasma free fraction correction
Plasma free fraction (f p ) values were available from 12 scans in seven subjects for the arterial blood, while all 14 values were available for the venous blood. In the arterial and venous blood, f p values were 5.3 %±0.9 % and 4.7 %±0.9 %, respectively, in the test scans (p=0.182), and 5.1 %±0.3 % and 4.8 %±1.0 %, respectively, in the retest scans (p=0.723). The overall relative difference in f p between the arterial and venous blood was 5.0 %±15.9 % (data from 12 studies in seven subjects). Mean TRV, SD of TRV, and mean of aTRV of f p were −6 %, 14 %, and 13 % for the arterial blood and −2 %, 33 %, and 25 % for the venous blood, respectively.
When V T was corrected for f p (V T /f p ), the intersubject variability was similar to that of V T . Mean CoV across the ROIs were 14.5 % for 2 T, 14.5 % for MA1, 18.0 % for EQ A,90-120 , and 21.1 % for EQ V,90-120 . With V T /f p correction, mean TRV was improved for 2 T, MA1, and EQ A,90-120 , across almost all ROIs, but SD of TRV and mean aTRV were increased (Tables 3, 4 
and 5).
Comparison of arterial and venous concentrations of [
F]FPEB
The arterial and venous plasma concentrations of [ 18 F]FPEB reached the same level at equilibrium. The correlation was excellent and the venous concentration (C V ) was 1 % higher than the arterial concentration (C A ) at The data presented are means±standard deviation, n=7 Fig. 3a) . Equality between the arterial and the venous concentrations occurred by~60 min p.i. The mean relative differences were 2.8±9 % at 60 -65 min p.i. and −0.3±9 % at 115 -120 min p.i. (Fig. 3b) .
EQ analysis using various time windows
Earlier time windows for estimating V T with EQ A and EQ V were evaluated to determine if scanning could be performed earlier. The time windows 80 -110 min, 70 -100 min, and The data presented are means±standard deviation, n=7 V T and V T /f p values were averaged across test and retest scans, and the mean and SD were calculated across the seven subjects. Retest V T and V T /f p from 2 T, MA1, and EQ A of three subjects were estimated using the input function from the test study of each subject scaled by the ratio of the injected doses ROI region of interest, 2 T two-tissue compartment model, MA1 multilinear analysis 1, EQ A equilibrium analysis using arterial input function, EQ V equilibrium analysis using venous input function n=7 For 2 T, MA1 and EQ A , values in three subjects were calculated using the retest V T estimated using the input function from the test study of each subject scaled by the injected dose TRV test-retest variability, ROI region of interest, 2 T two-tissue compartment model, MA1 multilinear analysis 1, EQ A equilibrium analysis using arterial input function, EQ V equilibrium analysis using venous input function n=7 For 2 T, MA1 and EQ A , values in three subjects were calculated using the retest V T estimated using the input function from the test study of each subject scaled by the injected dose TRV test-retest variability, SD standard deviation, ROI region of interest, 2 T two-tissue compartment model, MA1 multilinear analysis 1, EQ A equilibrium analysis using arterial input function, EQ V equilibrium analysis using venous input function EQ V ). The percent differences between the values for 60 -90 min and those for 90 -120 min were −1±7 % with EQ A and −3±5 % with EQ V . Shorter time windows were also evaluated to determine if the scanning time could be For 2 T, MA1 and EQ A , values in three subjects were calculated using the retest V T /f p estimated using the input function from the test study of each subject scaled by the injected dose aTRV absolute test-retest variability, ROI region of interest, 2 T two-tissue compartment model, MA1 multilinear analysis 1, EQ A equilibrium analysis using arterial input function, EQ V equilibrium analysis using venous input function For 2 T, MA1 and EQ A , values in three subjects were calculated using the retest V T /f p estimated using the input function from the test study of each subject scaled by the injected dose)
ICC intraclass correlation coefficient, ROI region of interest, 2 T two-tissue compartment model, MA1 multilinear analysis 1, EQ A equilibrium analysis using arterial input function, EQ V equilibrium analysis using venous input function For example, with EQ A , the mean TRV, SD TRVand mean of aTRV were −2 %, 16 %, and 12 % for V T,60-90 and −1 %, 15 %, and 12 % for V T,60-75 , compared to −4 %, 14 %, and 11 % for V T,90-120 . Also, the quality of V T images created using earlier and shorter time windows was comparable to those using data from 90 -120 min (Fig. 5) . Characteristics of BP ND with shorter and earlier time windows are shown in Fig. S2 of the Online Resource.
Discussion
The purpose of this study was to evaluate the test-retest reproducibility of [ and EQ V,90-120 overestimated V T in all ROIs by a mean of 9 % and 7 %, respectively. Values of BP ND estimated by three different methods also agreed well with each other. Compared to 2 T, EQ 90-120 underestimated BP ND by a mean of 11 %. This underestimation of regional BP ND resulted from overestimation of CWM V T by EQ A,90-120 and EQ V,90-120 (19 % and 17 %, respectively), which was larger than the mean overestimation of the other ROIs (9 % and 7 %, respectively). These results are consistent with the findings of our previous study [14] . In principle, V T corrected for plasma free fraction (f p ) of a radioligand (V T /f p ) is a more accurate estimate of receptor binding than V T itself, because V T values should be linearly proportional to f p . Correction for f p is particularly useful if there are between-group differences in f p and if the f p measurement is reliable. However, V T /f p is not always a more useful measure than V T , especially if additional noise is introduced by including f p , such as when this measurement is not reliable. The f p of [ F]FPEB appears to be a highly lipophilic ("sticky") compound that is adsorbed to the ultrafiltration devices used for f p analysis, as well as to certain infusion tubing. This may explain the larger intersubject variability of V T /f p compared to that of V T in this study.
As is often the case in studies over multiple days, full arterial blood samples were not available for the retest scans in three subjects. For these scans, input functions were created by scaling the arterial curve from the test study by the ratio of the injected doses. It is possible that this approach could have artificially reduced the apparent test-retest variance, as measurement of the arterial input function is a source of variability. To test the effect of input function scaling, TRV of V T values were calculated using a scaled input function based on the injected dose in all seven subjects. Interestingly, mean aTRV increased from −11 % to −16 % for both the 2 T and MA1 methods. Thus, it appears that using the same input function scaled for differences in injected dose did not always artificially reduce TRV. The mean and SD of TRV of V T estimated using the 2 T and MA1 methods were similar among these three subjects in whom a scaled input function was used for their retest studies ('scaled input group') and the four subjects who had original arterial input function for both test and retest studies ('original input group'). However, mean aTRV of V T by EQ A,90-120 was larger in the scaled input group than in the original input group (−9 % vs. −1 %). This does not appear to be due to scaling, because the mean TRV of V T by EQ V,90-120 was also larger for the scaled input group than for the original input group (7 % vs. −2 % (venous input functions were original in all subjects).
The arterial and venous plasma concentrations of [ 18 F]FPEB reached the same level during equilibrium. The correlation between them was excellent and the venous concentrations were only 1 % higher than the arterial concentrations on average at 90 -120 min. This result is different from that of our previous study, in which the venous plasma concentration was a mean of 7 % lower [14] . The difference may have originated from two sources. Study subjects were different and those who participated in the previous study had tissue TACs that were mostly increasing during the 90 -120 min period, while subjects in the present study had stable or somewhat decreasing TACs. In addition, the fitting method for metabolite analysis in the venous blood was simplified in the current analysis (see Methods).
Equilibrium was achieved in most regions. The mean negative rate of concentration change (−5±9 %/h) between 90 to 120 min suggests that, in this population, the bolus portion of the tracer delivery (K bol ) might be slightly too large. Interestingly, V T from the EQ methods showed better stability, with a mean percent difference between the values for 60 -90 min and 90 -120 min of −1 % and −3 % for EQ A and EQ V , respectively. This is consistent with theoretical expectations, whereby the magnitude of bias of the tissue-toplasma ratio compared to true V T in non-equilibrium conditions is nonlinearly related to plasma and tissue clearance rates [16] . Note that CWM showed a poorer equilibrium, which is not surprising since it has the lowest V T value and also has smaller rate constants, as it is a white matter region. If CWM is used as the reference region, BP ND values do not show the same stability as V T values, with a mean percent difference between the values for 60 -90 min and 90 -120 min of +8 % (Online Resources), consistent with larger percent reductions in the denominator (CWM) than in the numerators. Moving the equilibrium period later than 120 min would likely allow the CWM to obtain adequate stability if it is to be used as the reference region in estimating BP ND by EQ.
CWM was selected as the reference region in our study because it showed the lowest V T (5.7 ± 0.6 with kinetic modeling and 6.7 ± 0.9 with EQ A ). In another study of [ 18 F]FPEB in humans [21] , the pons was used to calculate BP ND since it was the region with the lowest V T in that study (about 5 mL/cm 3 ). CGM V T was higher than the CWM V T , indicating that there is either specific binding in the CGM, or that the nondisplaceable volume of distribution (V ND ) is different between the two regions. V ND may be different between gray and white matter due to different tissue properties such as lipophilicity. However, it is likely that even a biased estimate of V ND that might be driven by CWM might still provide a very useful measure of BP ND , providing there are no diseasespecific abnormalities in the white matter. If V ND is the same in the two regions, then BP ND in the CGM is 0.8±0.1 by 2 T, 0.7±0.1 by MA1 and 0.8±0.2 with EQ A .
An in vitro binding study has revealed small but positive specific binding of [ 18 F]FPEB in the cerebellar tissue in humans as well as in rats and rhesus monkeys [19] . [20, 27, 28] . Thus, based on our findings and other published data, it appears that there is specific mGluR5 binding in the cerebellum. Small amounts of specific binding in a reference region or small differences in V ND between reference regions and ROIs will affect quantification and interpretation of results in different ways, based on the experimental design, e.g., different errors will occur for within-subject occupancy studies and cross-sectional comparisons of patients and controls.
However, it may still be useful to estimate BP ND using the cerebellum as the reference region, providing investigators clearly spell out their assumptions in its use. In this case, whether to use the CGM or CWM as the reference region must be carefully considered. For example, with [ 18 F]FPEB, selecting the CWM as the reference region may include the least possible specific binding but have poorer TRV than the CGM for EQ analysis, due to slower kinetics in the white matter than the gray matter, as well as noise effects due to region size differences (see Online  Resource Tables S2 and S3 ). To avoid this issue, using V T as an outcome measure may be advantageous, as it is not influenced by specific binding in the cerebellum. However, V T is more sensitive to errors in the input function. BP ND may be a better measure if there is no difference in specific binding between groups or patient states in the reference region. From a test-retest reproducibility point of view, [ 18 F]FPEB BP ND was better than V T in the 2 T and MA1 analyses, while BP ND was equivalent to V T in the EQ analyses. Further, since a portion of the V T value reflects nondisplaceable binding (V ND ), comparable TRV of BP ND and V T means greater signal-to-noise contrast for BP ND , since 100 % of the BP ND value is the receptor "signal" (assuming the reference region is correct).
Earlier as well as shorter scanning showed promising results with [ 18 F]FPEB, in that the results for the time window 60 -75 min were comparable to those for 90 -120 min. [ 18 F]FPEB binding values (V T and BP ND by EQ analysis) between the two time windows showed an excellent correlation and the test-retest reproducibility was similar between these two time windows. Earlier and shorter scanning could be more convenient for patients, reduce motion issues during scanning, and enhance efficiency of the scanning schedule. However, the optimal conditions should be determined for each patient population.
In this study, using a bolus plus constant infusion, we demonstrated that the test-retest reproducibility of [ 18 F]FPEB is very good and in agreement between venous and arterial blood measurements during equilibrium. Considering this test-retest reproducibility and the simplicity of scanning and analysis at equilibrium that does not require arterial blood sampling, EQ is considered to be the method of choice to estimate mGluR5 availability in the human brain using [ 
